|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2010-12-3
|
|
pubmed:abstractText |
among multidrug-resistant HIV-1-infected patients, enfuvirtide has demonstrated sustained efficacy, but long-term use is inconvenient due to twice-daily subcutaneous injections which often induce injection-site reactions. We investigated whether a switch from enfuvirtide to raltegravir, an orally available HIV-integrase inhibitor, may improve health-related quality of life (HRQoL).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1528-4336
|
|
pubmed:author |
pubmed-author:AboulkerJean-PierreJP,
pubmed-author:BouletThomasT,
pubmed-author:BraunJoséphineJ,
pubmed-author:CharreauIsabelleI,
pubmed-author:Easier-Anrs 138 Study Group,
pubmed-author:MolinaJean-MichelJM,
pubmed-author:MorlatPhilippeP,
pubmed-author:PavieJulietteJ,
pubmed-author:PirothLionelL,
pubmed-author:ReynesJacquesJ,
pubmed-author:SpireBrunoB
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
283-93
|
|
pubmed:meshHeading |
pubmed-meshheading:21126958-Administration, Oral,
pubmed-meshheading:21126958-Adult,
pubmed-meshheading:21126958-Chi-Square Distribution,
pubmed-meshheading:21126958-Female,
pubmed-meshheading:21126958-HIV Envelope Protein gp41,
pubmed-meshheading:21126958-HIV Fusion Inhibitors,
pubmed-meshheading:21126958-HIV Infections,
pubmed-meshheading:21126958-HIV Integrase Inhibitors,
pubmed-meshheading:21126958-HIV-1,
pubmed-meshheading:21126958-Humans,
pubmed-meshheading:21126958-Injections, Subcutaneous,
pubmed-meshheading:21126958-Male,
pubmed-meshheading:21126958-Middle Aged,
pubmed-meshheading:21126958-Peptide Fragments,
pubmed-meshheading:21126958-Prospective Studies,
pubmed-meshheading:21126958-Pyrrolidinones,
pubmed-meshheading:21126958-Quality of Life,
pubmed-meshheading:21126958-Questionnaires,
pubmed-meshheading:21126958-RNA, Viral
|
|
pubmed:articleTitle |
Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).
|
|
pubmed:affiliation |
INSERM SC10, Villejuif, France. thomas.boulet@inserm.fr
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
